Sigma receptor inhibitors

1. A compound of general formula (I):

wherein

R 1 represents substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted aryl; or substituted or unsubstituted cycloalkyl;

R 2 represents a hydrogen atom; F; Cl; Br; I; CF 3 ; OH; SH; CN; methyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted, non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl; a (C═O)—R 7 group; a (C═O)—O—R 8 group; a S(O) t —R 9 group; or a (C═O)—NR 10 R 11 group;

R 3 represents a hydrogen atom; F; Cl; Br; I; CF 3 ; OH; SH; NH 2; CN; substituted or unsubstituted alkyl; substituted or unsubstituted alkenyl; substituted or unsubstituted alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl; a (C═O)—R 7 group; a (C═O)—O—R 8 group; a S(O) t —R 9 group; or a (C═O)—NR 10 R 11 group;

R 4 and R 5 form, together with the nitrogen atom to which they are attached, a substituted or unsubstituted heterocyclyl group;

X represents an oxygen atom or a CH—R 12 group wherein R 12 is selected from H, CH 3 , SH, OH, NH 2 , CF 3 , Cl, F, Br, I, and CN;

m is 1, 2, 3 or 4;

n is 1, 2, 3 or 4;

t is 1, 2 or 3; and

R 7 , R 8 , R 9 , R 10 and R 11 , identical or different, represent a hydrogen atom; substituted or unsubstituted C 1-6 alkyl; substituted or unsubstituted C 2-6 alkenyl; substituted or unsubstituted C 1-6 alkoxy; substituted or unsubstituted cycloalkyl; substituted or unsubstituted aryl; substituted or unsubstituted, aromatic or non-aromatic heterocyclyl; substituted or unsubstituted cycloalkylalkyl; substituted or unsubstituted arylalkyl; substituted or unsubstituted, aromatic or non-aromatic heterocyclylalkyl;

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

2. The compound according to claim 1 , wherein R 1 is a 5- to 10 membered substituted or unsubstituted, aromatic or non-aromatic heterocyclyl group which preferably contains N, O or S as ring member; a 5 to 10 membered substituted or unsubstituted aryl group; or a 5 to 10 membered substituted or unsubstituted cycloalkyl group.

3. The compound according to claim 2 , wherein R 1 is substituted or unsubstituted cyclopentyl, substituted or unsubstituted cyclohexyl, substituted or unsubstituted phenyl, substituted or unsubstituted naphthyl, substituted or unsubstituted thiophene, substituted or unsubstituted benzothiophene, substituted or unsubstituted benzofuran, substituted or unsubstituted pyridine or substituted or unsubstituted quinoline.

4. The compound according to claim 3 , wherein R 1 is selected from the group consisting of: 2-thienyl, 3-thienyl, 2,5-dichloro-3-thienyl, 2,3-dichloro-5-thienyl, 2,3-dichloro-4-thienyl, 2-benzothienyl, 3-benzothienyl, 4-benzothienyl, 5-benzothienyl, 7-benzothienyl, 2-benzofuryl, 5-benzofuryl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-quinolyl, 3-quinolyl, 5-quinolyl, 6-quinolyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, cyclopentyl, cyclohexyl, 7-hydroxy-2-naphthyl, 6-hydroxy-2-naphthyl, 5-hydroxy-2-naphthyl, 6-fluoro-2-naphthyl, 6-methoxy-2-naphthyl, 6-bromo-2-naphthyl, 6-hydroxymethyl-2-naphthyl, 6-fluromethyl-2-naphthyl, 7-hydroxy-1-naphthyl, 6-hydroxy-1-naphthyl, 5-hydroxy-1-naphthyl, 5-fluoro-1-naphthyl, 5-bromo-1-naphthyl and 1-naphthyl.

5. The compound according to claim 1 , wherein R 2 is H or methyl and R 3 is H or substituted or unsubstituted C l-6 alkyl group.

6. The compound according to claim 5 , wherein R 2 is methyl and R 3 is H, or R 2 and R 3 are simultaneously H or methyl.

7. The compound according to claim 1 , wherein R 4 and R 5 form together a morpholine-4-yl group, a piperidine group, pyrrolidine group or a piperazine-4-yl group.

8. The compound according to claim 1 , wherein each m and n independently represent 1 or 2.

9. The compound according to claim 1 selected from the group consisting of:

4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

4-(2-((5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

4-(3-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)propyl)morpholine,

4-(3-(5-methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)propyl)morpholine,

4-(2-(2-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)ethoxy)ethyl)morpholine,

4-(2-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

4-(3-(1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)propyl)morpholine,

1-(3,4-dichlorophenyl)-5-methyl-3-((2-(pyrrolidin-1-yl)ethoxy)methyl)-1H-pyrazole,

1-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperidine,

1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone,

(2S,6R)-4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)-2,6-dimethylmorpholine,

4-(2-((5-methyl-1-(quinolin-3-yl)-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

4-(4-(1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)butyl)morpholine,

4-(3-(5-methyl-1-(quinolin-3-yl)-1H-pyrazol-3-yl)propyl)morpholine,

4-(2-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

4-(2-((1-(3,4-dichlorophenyl)-4,5-dimethyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

4-(3-(1-(quinolin-3-yl)-1H-pyrazol-3-yl)propyl)morpholine,

4-(4-(1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)butyl)morpholine,

4-(4-(5-methyl-1-(quinolin-3-yl)-1H-pyrazol-3-yl)butyl)morpholine,

4-(3-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)propyl)morpholine,

4-(2-((1-cyclopentyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

1-(4-(2-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone hydrochloride,

(3S,5R)-1-(2-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)-3,5-dimethylpiperazine hydrochloride,

4-(2-(2-(1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)ethoxy)ethyl)morpholine hydrochloride,

4-(2-((1-cyclohexyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine hydrochloride,

4-(2-((1-cyclohexyl-4,5-dimethyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine hydrochloride,

1-(4-(2-((1-cyclohexyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone,

1-(4-(3-((1-cyclohexyl-1H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone,

1-(4-(4-((1-cyclohexyl-1H-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanone,

1-(4-(4-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanone,

1-(4-(3-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone,

1-(4-(2-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone

1-(4-(3-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone,

1-(4-(4-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)butyl)piperazin-1-yl)ethanone,

1-(4-(3-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone,

1-(4-(3-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone,

1-(4-(3-((1-(3,4-difluorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)propyl)piperazin-1-yl)ethanone,

1-(4-(2-((1-(3,4-difluorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone,

1-(4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)ethanone,

4-(2-((1-(3,4-difluorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

4-(2-((1-(3,4-difluorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)morpholine,

4-(3-((1-(3,4-difluorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)propyl)morpholine,

1-(4-(2-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one,

1-(4-(2-((1-cyclohexyl-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one,

1-(4-(2-((1-cyclohexyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one,

1-(4-(2-((1-cyclohexyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one,

1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one,

1-(4-(2-((1-(3,4-dichlorophenyl)-5-methyl-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one,

1-(4-(2-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)propan-1-one, and

1-(4-(2-((1-(3,4-dichlorophenyl)-1H-pyrazol-3-yl)methoxy)ethyl)piperazin-1-yl)-2-methylpropan-1-one,

or a pharmaceutically acceptable salt, prodrug or solvate thereof.

10. A process for the preparation of a compound of formula (I) as defined in claim 1 , or a salt, isomer or solvate thereof, which is:

a) a process which comprises the reaction of a compound of formula (II)

with a compound of formula (III)

in which LG represents a leaving group;

b) a process which comprises the oxidation of a compound of formula (II) to afford a compound of formula (VII)

followed by the reaction of the compound of formula (VII) with a phosphonium salt of formula (VIII)

to afford a compound of formula (IX)

and reduction of the compound of formula (IX);

c) a process which comprises the oxidation of a compound of formula (II) to afford a compound of formula (VII)

followed by the reaction of the compound of formula (VII) with a suitable phosphonium salt and subsequent acid hydrolysis to afford a compound of formula (XI)

reduction of the compound of formula (XI) and subsequent reaction with a compound of formula (III)

in which LG represents a leaving group;

d) a process which comprises reaction of 3-acetyl-6-methyl-pyran-2,4-dione with magnesium and subsequent reaction with a compound of formula (V):

to afford a compound of formula (XV)

and reduction of the compound of formula (XV) and subsequent reaction with a compound of formula (III)

in which LG represents a leaving group;

e) a process which comprises the oxidation of a compound of formula (II) to afford a compound of formula (VII)

followed by the reaction of the compound of formula (VII) with a phosphonium salt of formula (XVII)

to afford a compound of formula (XVII)

and reduction of the compound of formula (XVIII).

11. A medicament comprising at least one compound of formula (I) as defined in any of claim 1 , or a pharmaceutically acceptable salt, prodrug or solvate thereof and a pharmaceutically acceptable excipient.

12. A method for the manufacture of a medicament comprising combining the compound as defined in claim 1 with a pharmaceutically acceptable excipient.

13. A method for the treatment of a sigma receptor-mediated disease or condition, comprising administering to a patient a therapeutically amount of the compound as defined in claim 1 .

14. The method according to claim 13 , wherein the disease comprises diarrhea; lipoprotein disorders; migraine; obesity; elevated triglyceride levels; chylomicronemia; dysbetalipoproteinemia; hyperlipoproteinemia; hyperlipidemia; mixed hyperlipidemia; hypercholesterolemia; hypertriglyceridemia; sporadic hypertriglyceridemia; inherited hypertriglyceridemia; arthritis; hypertension; arrhythmia; ulcer; demyelinating diseases; addiction to drugs and chemical substances including cocaine, amphetamine, ethanol and nicotine; tardive dyskinesia; ischemic stroke; epilepsy; stroke; stress; psychotic conditions; or inflammation.

15. The method according to claim 13 , wherein the disease is pain.

16. Compound of general formula (I) as defined in claim 1 for use as a pharmacological tool.

17. The method according to claim 13 , wherein the disease is depression, anxiety or schizophrenia.

18. The method according to claim 15 , wherein the pain is neuropathic pain, inflammatory pain or other pain conditions involving allodynia and/or hyperalgesia.

19. The compound according to claim 5 , wherein R 2 and R 3 are independently H or methyl.